Log in
NASDAQ:FATE

Fate Therapeutics News Headlines

$48.36
+0.65 (+1.36 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$47.06
Now: $48.36
$48.60
50-Day Range
$30.41
MA: $39.91
$49.04
52-Week Range
$12.59
Now: $48.36
$51.10
Volume319,664 shs
Average Volume1.02 million shs
Market Capitalization$4.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57

Headlines

Fate Therapeutics (NASDAQ FATE) News Headlines Today

Source:
DateHeadline
Fate Therapeutics (NASDAQ:FATE) Cut to "Strong Sell" at Zacks Investment ResearchFate Therapeutics (NASDAQ:FATE) Cut to "Strong Sell" at Zacks Investment Research
marketbeat.com - October 22 at 10:33 AM
BidaskClub Upgrades Fate Therapeutics (NASDAQ:FATE) to "Buy"BidaskClub Upgrades Fate Therapeutics (NASDAQ:FATE) to "Buy"
marketbeat.com - September 30 at 1:17 AM
Fate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by BidaskClubFate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by BidaskClub
marketbeat.com - August 21 at 1:04 AM
Technical Watchlist: Meritor, Banc of California, Fate Therapeutics (FATE)Technical Watchlist: Meritor, Banc of California, Fate Therapeutics (FATE)
marketbeat.com - August 3 at 2:08 PM
Fate Therapeutics to Present at Jefferies Cell Therapy Virtual SummitFate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
finance.yahoo.com - October 22 at 10:32 PM
Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual MeetingFate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - October 22 at 10:32 PM
Fate Therapeutics (NASDAQ:FATE) Shares Up 7.3%Fate Therapeutics (NASDAQ:FATE) Shares Up 7.3%
americanbankingnews.com - October 22 at 7:52 PM
Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7.7% Following Insider SellingFate Therapeutics (NASDAQ:FATE) Stock Price Down 7.7% Following Insider Selling
americanbankingnews.com - October 21 at 6:17 PM
Insider Selling: Fate Therapeutics Inc (NASDAQ:FATE) General Counsel Sells 29,199 Shares of StockInsider Selling: Fate Therapeutics Inc (NASDAQ:FATE) General Counsel Sells 29,199 Shares of Stock
americanbankingnews.com - October 20 at 5:07 PM
Reviewing MeiraGTx (NASDAQ:MGTX) and Fate Therapeutics (NASDAQ:FATE)Reviewing MeiraGTx (NASDAQ:MGTX) and Fate Therapeutics (NASDAQ:FATE)
americanbankingnews.com - October 16 at 3:14 AM
Barclays Reaffirms "Overweight" Rating for Fate Therapeutics (NASDAQ:FATE)Barclays Reaffirms "Overweight" Rating for Fate Therapeutics (NASDAQ:FATE)
americanbankingnews.com - October 15 at 9:12 AM
A Closer Look At Fate TherapeuticsA Closer Look At Fate Therapeutics
seekingalpha.com - October 12 at 5:14 PM
Fate Therapeutics (NASDAQ:FATE) Reaches New 12-Month High at $48.98Fate Therapeutics (NASDAQ:FATE) Reaches New 12-Month High at $48.98
americanbankingnews.com - October 12 at 10:56 AM
Fate Therapeutics Inc. Register (F6T.SG)Fate Therapeutics Inc. Register (F6T.SG)
au.finance.yahoo.com - October 10 at 1:19 AM
Fate Therapeutics (NASDAQ:FATE) Trading 6% Higher Fate Therapeutics (NASDAQ:FATE) Trading 6% Higher
americanbankingnews.com - October 7 at 9:03 PM
Fate Therapeutics (NASDAQ:FATE) Hits New 12-Month High at $42.27Fate Therapeutics (NASDAQ:FATE) Hits New 12-Month High at $42.27
americanbankingnews.com - October 6 at 10:46 AM
Fate Therapeutics (NASDAQ:FATE) Shares Gap Down to $40.61Fate Therapeutics (NASDAQ:FATE) Shares Gap Down to $40.61
americanbankingnews.com - October 5 at 9:43 AM
Fate Therapeutics (NASDAQ:FATE) Trading Down 6.2%Fate Therapeutics (NASDAQ:FATE) Trading Down 6.2%
americanbankingnews.com - October 2 at 7:39 PM
Hedge Funds Have Never Been This Bullish On Eagle Materials, Inc. (EXP)Hedge Funds Have Never Been This Bullish On Eagle Materials, Inc. (EXP)
finance.yahoo.com - September 9 at 10:56 AM
Protein Therapeutic Market 2020 Predictable to Witness Sustainable Evolution Over 2026Protein Therapeutic Market 2020 Predictable to Witness Sustainable Evolution Over 2026
marketwatch.com - September 7 at 7:11 PM
Fate Therapeutics Announces September Investor EventsFate Therapeutics Announces September Investor Events
finance.yahoo.com - September 4 at 10:17 AM
Indapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business OfficerIndapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business Officer
finance.yahoo.com - August 31 at 11:45 PM
Interesting FATE Put And Call Options For October 16thInteresting FATE Put And Call Options For October 16th
nasdaq.com - August 25 at 2:40 PM
Fate Therapeutics gets new CFOFate Therapeutics gets new CFO
seekingalpha.com - August 19 at 10:52 AM
Fate Therapeutics Appoints Edward Dulac as Chief Financial OfficerFate Therapeutics Appoints Edward Dulac as Chief Financial Officer
finance.yahoo.com - August 19 at 10:52 AM
How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own?How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own?
finance.yahoo.com - August 11 at 4:12 PM
What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)?What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)?
finance.yahoo.com - August 11 at 4:12 PM
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call TranscriptFate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 6 at 3:27 AM
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue EstimatesFate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 5 at 10:27 PM
Fate Therapeutics EPS misses by $0.10, misses on revenueFate Therapeutics EPS misses by $0.10, misses on revenue
seekingalpha.com - August 5 at 5:27 PM
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational ProgressFate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
finance.yahoo.com - August 5 at 5:27 PM
Fate Therapeutics Q2 2020 Earnings PreviewFate Therapeutics Q2 2020 Earnings Preview
seekingalpha.com - August 4 at 9:24 PM
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual ConferenceFate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 4 at 4:23 PM
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial ResultsFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
finance.yahoo.com - July 29 at 6:54 PM
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseFate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - July 28 at 2:05 PM
Were Hedge Funds Right About Piling Into Fate Therapeutics Inc (FATE)?Were Hedge Funds Right About Piling Into Fate Therapeutics Inc (FATE)?
finance.yahoo.com - July 16 at 2:38 PM
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular TherapiesFate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
finance.yahoo.com - July 14 at 9:25 AM
Fate's IND Application for CAR T Cell Therapy Gets FDA NodFate's IND Application for CAR T Cell Therapy Gets FDA Nod
finance.yahoo.com - July 10 at 1:26 PM
Fate Therapeutics on go to advance CAR T candidate FT819 into the clinicFate Therapeutics on go to advance CAR T candidate FT819 into the clinic
seekingalpha.com - July 9 at 9:28 AM
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell TherapyFate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
finance.yahoo.com - July 9 at 9:28 AM
First Week of FATE February 2021 Options TradingFirst Week of FATE February 2021 Options Trading
www.nasdaq.com - June 19 at 3:06 PM
Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)
finance.yahoo.com - June 15 at 2:33 PM
If You Invested $1,000 in Fate Therapeutics IPO, This Is How Much Money Youd Have NowIf You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now
finance.yahoo.com - June 13 at 12:46 PM
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesFate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - June 11 at 5:36 PM
What does the future hold for the Fate Therapeutics Inc share price?What does the future hold for the Fate Therapeutics Inc share price?
uk.finance.yahoo.com - June 10 at 10:12 AM
Heres Why Fate Therapeutics Rose 18.4% in MayHere's Why Fate Therapeutics Rose 18.4% in May
finance.yahoo.com - June 9 at 6:32 PM
BRIEF-Fate Therapeutics Announces Pricing Of Public Offering Of 6,181,562 Shares At A Price Of $28.31 Per ShareBRIEF-Fate Therapeutics Announces Pricing Of Public Offering Of 6,181,562 Shares At A Price Of $28.31 Per Share
www.reuters.com - June 9 at 8:31 AM
Fate Therapeutics prices equity offering at $28.31Fate Therapeutics prices equity offering at $28.31
seekingalpha.com - June 9 at 8:31 AM
Fate Therapeutics Announces Pricing of Public Offering of Common StockFate Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 9 at 8:31 AM
Fate Therapeutics Announces Proposed Public Offering of Common StockFate Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 8 at 7:40 PM
Global NK Cell Therapy Market 2020 Market Size, Business Opportunities, Current Trends, Share, Challenges and CAGR Status and Forecast to 2026Global NK Cell Therapy Market 2020 Market Size, Business Opportunities, Current Trends, Share, Challenges and CAGR Status and Forecast to 2026
www.marketwatch.com - June 4 at 6:59 AM
FDA clears Fate Therapeutics IND for FT538FDA clears Fate Therapeutics' IND for FT538
seekingalpha.com - May 20 at 12:39 PM
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell TherapyFate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
finance.yahoo.com - May 20 at 12:39 PM
Heres Why Big Buyers Are Excited About This Cancer Immunotherapy StockHere's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock
www.fool.com - May 15 at 8:57 AM
This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.